Clinical effect of immunohistochemical detection in pathological
diagnosis of breast cancer

doi:10.3760/cma.j.issn.1007-1245.2022.11.003

Abstract

Abstract: Objective　To analyze the clinical effect of immunohistochemical detection in the pathological diagnosis of breast cancer. Methods　The subjects of the study were 241 female breast cancer patients who were admitted to Zhongshan Hospital, Dalian University from January 1, 2019 to August 1, 2021. All the patients underwent surgical treatment after enrollment. According to the surgical resection of breast tumor specimens, the ER+ (estrogen receptor positive) PR+ (progesterone receptor positive) patients were included in the positive group (121 cases), and the ER- (estrogen receptor negative) and PR- (progesterone receptor negative) patients were included in the negative group (120 cases). The positive group were (56.87±4.35) years old, and the negative group (57.13±4.46). Both groups underwent immunohistochemical detection, and the results were compared. The independent-sample t test was applied. Results　The proportions of HER-2 (human epidermal growth factor receptor) (+) and HER-2 (-) of breast tumor specimens and the axillary lymph node metastasis rate were 23.96% (29/121), 76.03% (92/121), and 31.40% (38/121) in the positive group, and were 85.00% (102/120), 15.00% (18/120), and 65.83% (79/120) in the negative group, with statistical differences (all P<0.05). Conclusion　Immunohistochemical detection can provide effective references for the pathological diagnosis of breast cancer, clarify the positive rate of HER-2 and axillary lymph node metastasis, and point out an accurate direction for further clinical intervention, and is conducive to the improvement of the prognosis.

Key words: Breast cancer, Pathological diagnosis, Immunohistochemical detection

摘要： 目的　探讨分析乳腺癌病理诊断中免疫组织化学检测的临床效果。方法　研究对象为2019年1月1日至2021年8月1日期间大连大学附属中山医院收治的241例乳腺癌患者，入组后均行手术治疗，并按照手术切除后乳腺肿瘤标本雌激素受体阳性（ER+）、孕激素受体阳性（PR+）纳入阳性组，将雌激素受体阴性（ER-）、孕激素受体阴性（PR-）纳入阴性组，其中阳性组121例、阴性组120例，参与本次研究患者均为女性，阳性组年龄（56.87±4.35）岁，阴性组年龄（57.13±4.46）岁。两组患者均接受免疫组织化学检测，然后对比检验结果。统计学方法采用独立样本t检验、χ²检验。结果　阳性组乳腺肿瘤标本人表皮生长因子受体2（HER-2）（+）低于阴性组［23.96%（29/121）比85.00%（102/120）］，HER-2（-）高于阴性组［76.03%（92/121）比15.00%（18/120）］，阳性组腋窝淋巴结转移率低于阴性组［31.40%（38/121）比65.83%（79/120）］，差异均有统计学意义（均P<0.05）。结论　免疫组织化学检测可为乳腺癌病理诊断提供有效参考，同时明确HER-2阳性率及腋窝淋巴结转移情况，并为展开临床进一步干预指明准确方向，有利于疾病预后质量的改善与提升。

关键词: 乳腺癌, 病理诊断, 免疫组织化学检测

Yang Yang, Li Jianhua, Cheng Yao, Zhu Ruiping. Clinical effect of immunohistochemical detection in pathological diagnosis of breast cancer [J]. International Medicine and Health Guidance News, 2022, 28(11): 1492-1494.

杨杨, 李建华, 程瑶, 朱瑞萍. 乳腺癌病理诊断中免疫组织化学检测的临床效果分析[J]. 国际医药卫生导报, 2022, 28(11): 1492-1494.

References

[1] 刘兆琳. 乳腺癌病理诊断中免疫组织化学检测的效果分析[J]. 中国实用医药,2020,15(23):4-7. DOI:10.14163/j.cnki.11-5547/r.2020.23.002.

[2] 彭理,赵佳琳,赵大春,等. 免疫组织化学指标在乳腺癌原发灶和复发转移灶之间的表达差异[J]. 中国医学科学院学报,2019,41(5):673-677. DOI:10.38/j.issn.1000-503X.10940.

[3] 马福华. 乳腺肿瘤患者病理诊断中使用免疫组化检查的准确性分析[J]. 临床研究,2021,29(9):135-137.

[4] 车畅. 乳腺癌病理诊断中免疫组织化学检测的临床价值探讨[J]. 基层医学论坛,2020,24(13):1870-1871. DOI:10.19435/j.1672-1721.2020.13.056.

[5] 姜秋利,郑景妹,刘坤,等. 免疫组织化学检测在乳腺疾病病理诊断中的应用[J]. 深圳中西医结合杂志,2020,30(19):45-46. DOI:10.16458/j.cnki.1007-0893.2020.19.019.

[6] 阎红琳,袁修学,吴昊,等. CD68、上皮性钙黏蛋白、转化生长因子-β1在乳腺癌中的表达及意义[J]. 中华内分泌外科杂志,2019,13(2):97-102. DOI:10.3760/cma.j.issn.1674- 6090.2019.02.003.

[7] 魏雪,李锐,王璇,等. 乳腺癌组织切片经免疫组织化学染色后荧光原位杂交检测的再利用[J]. 中华病理学杂志,2019,48(8):636-638. DOI:10.3760/cma.j.issn.0529‐5807. 2019.08.010.

[8] 侯欣喜,耿文静,吴又明. MMP-9和MTDH在乳腺癌中的表达及其临床病理学特征的关系[J]. 诊断病理学杂志,2019,26(11):728-730,759. DOI:10.3969/j.issn.1007-8096. 2019.11.005.

[9] 胡幸,丁义涛. 数字化X射线摄影检查对乳腺癌患者的诊断价值及与临床病理关系分析[J]. 中国医学装备,2019,16(2):43-45. DOI:10.3969/J.ISSN.1672-8270.2019.02.011.

[10] 张琰,吴云风,兰希,等. 免疫组织化学法检测三阴乳腺癌Ki-67抗原的改良方法研究[J]. 检验医学与临床,2019,16(8):1040-1043. DOI:10.3969/j.issn.1672-9455. 2019.08.010.

[11] 王娟,黄炳臣,吴雪铭,等. ER、PR、Her-2、VEGF、p53和Ki67在乳腺癌中的表达及临床病理意义分析[J]. 右江医学,2019,47(3):166-171. DOI:10.3969/j.issn.1003-1383. 2019.03.002.

[12] 唐月阳,叶入裴,夏天,等. 探讨影响FISH检测乳腺癌免疫组化HER2(2+)扩增状态的因素及其与临床病理的意义[J]. 川北医学院学报,2020,35(2):243-247. DOI:10.3969/j.issn.1005-3697.2020.02.017.

Clinical effect of immunohistochemical detection in pathological diagnosis of breast cancer

乳腺癌病理诊断中免疫组织化学检测的临床效果分析

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 7

Recommended Articles

Metrics

[1]	Yuan Chenye, Li Yuqun. Evaluation of the effect of chronic disease self-management model in patients with postoperative lymphedema of breast cancer [J]. International Medicine and Health Guidance News, 2022, 28(8): 1126-1130.
[2]	Wu Xueting, Chen Xiaoyi, Wu Yiwen, Cai Yongna, Xiao Mingyue, Chen Fengjuan, Han Qianglin, Qiu Shaodong, Zhu Zhiming, Chen Fei. Advances in the application of ultrasound radiomics in breast cancer [J]. International Medicine and Health Guidance News, 2022, 28(4): 484-487.
[3]	Yuan Chenye, Zhou Zhiyin. Effect of management mode based on smart medical system in prevention of lymphedema in breast cancer patients after surgery [J]. International Medicine and Health Guidance News, 2022, 28(3): 336-340.
[4]	Yu Wenlong, Yin Xiaowei, Yang Yuzhu, Xu Yanmei. One case of giant breast adenosquamous carcinoma and literature review [J]. International Medicine and Health Guidance News, 2022, 28(3): 419-421.
[5]	Fang Yongwen, Fang Jianlan, Liu Biaoshui, Yao Wenyan, Lin Xiaosheng, Lin Chengguang, Xiao Liangjie. Application of simulated reduction verification in intensity modulated radiotherapy for breast cancer patients [J]. International Medicine and Health Guidance News, 2022, 28(11): 1482-1485.
[6]	Cheng Chen, Li Xueping, Xu Yi, Zhao Hongyan, Zhao Haitao. Expressions of Ki-67, EGFR, and E-cad in breast cancer and their effects on prognosis [J]. International Medicine and Health Guidance News, 2022, 28(11): 1486-1491.
[7]	Kang Mengling, Li Liangfang, Liu Dongdong, Huang Lezhen. Investigation on constitution types of traditional Chinese medicine, Kupperman score, and treatment methods of perimenopausal patients with breast cancer [J]. International Medicine and Health Guidance News, 2022, 28(11): 1495-1499.